Join the Galcanezumab group to help and get support from people like you.
Galcanezumab News
FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache
INDIANAPOLIS, June 04, 2019 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) injection (300 mg) for the t...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults
INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg i...
Further information
Related condition support groups
Cluster Headaches, Migraine Prevention, Migraine Prophylaxis, Chronic Migraine, Headache, Migraine